Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Novartis ADR representing 1 Ord Shs NVS

Healthcare
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:NVS)

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

PR Newswire April 15, 2024

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

GlobeNewswire April 11, 2024

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

PR Newswire April 6, 2024

Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

GlobeNewswire February 14, 2024

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)

PR Newswire December 10, 2023

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH

PR Newswire December 6, 2023

Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

PR Newswire September 11, 2023

KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

PR Newswire June 8, 2023

Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets

GlobeNewswire March 6, 2023
View More News ››

Opinion & Analysis (NYSE:NVS)

EpiPen Rival Lands Major Partner

Streetwise Reports July 3, 2018

Biotech Round-Up: M&As, Financings and Immuno-Oncology

Streetwise Reports April 19, 2018

Analysts take note as small-cap biotech completes early enrollment for Phase 3 trial

The Life Sciences Report July 6, 2017

Big pharma sets its sights on NASH epidemic

The Life Sciences Report May 18, 2017

Stellar Biotechnologies (SBOT:NASDAQ) could rise with KLH vaccine trial success

The Life Sciences Report March 2, 2017

Partnerships propel Stellar Biotechnologies' vaccine technology

The Life Sciences Report June 22, 2016
View More Opinion ››

Bullboard Posts (NYSE:NVS)

Medicare's Ambitious Drug Price Negotiation Plan: President

Just In: $NVS Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50...
whytestocks - March 7, 2024

India Oral Hygiene Market Size and Trends 2027

The IMARC Group provides extensive analysis of the India Oral Hygiene industry covering the market trends, investment opportunities...
Imarcgroup - September 14, 2022

RE:RE:IVERMICTIN KILLS COVID 19 !

THE FAUCI INDICTMENT (Video) — SOTN: Alternative News ...   Oct 09, 2021 · THE FAUCI INDICTMENT…...
zeropointenergy - October 16, 2021

RE:IVERMICTIN KILLS COVID 19 !

Dr. Richard Bartlett on Budesonide, the Silver Bullet ... https://www.thethinkingconservative.com/dr-richard...
zeropointenergy - October 9, 2021

IVERMICTIN KILLS COVID 19 !

 NICE China Reports Zero New Locally Acquired Covid-19 Cases for Fourth Day in a Row  
zeropointenergy - October 9, 2021

ONE DRUG PILL WIPES OUT COVID 19!

India's Ivermectin Blackout - Part V: The Secret Revealed ...   Sep 27, 2021 · By September 12, 2021...
zeropointenergy - October 6, 2021
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »